Agents and Actions

, Volume 9, Issue 5–6, pp 527–533 | Cite as

Therapeutic effect, ofβ-[1-phenyl-5-bis(β-chloroethyl)-amino-benzimidazolyl-(2)-Dl-alanin (ZIMET 3164) on immune complex nephritis of NZB hyhrid mice

  • J. Güttner
Immunosuppression and Inflammation


β-[1-Phenyl-5-bis(β-chloroethyl)-amino-benzimid-azolyl-(2)]-Dl-alanin (ZIMET 3164), a highly immuno-suppressive but moderately cytostatic agent, was found to be able to prevent the progression of spontaneous murine immune complex nephritis in a dose-dependent fashion. For experiments, BCG-stimulated conventional female (NMRI×NZB)F1 mice suffering from rapidly progressive nephritis, BCG-stimulated and unilaterally nephrectomized (NMRI×NZB)F1 females, and (AB/Jena×NZB)F1 females characterized by a prolonged course of the disease were used. The beneficial effect was quantified by fluorescence photometry and histometry, and semiquantitatively detected by estimation of the extent of damage of individual glomerular structures when histometric methods were unsuited. Treatment of young adult animals characterized by slight to moderate glomerular lesions was more effective than of older ones with advanced nephritis. At equi-immunosuppressive dose levels ZIMET 3164 was about twice as effective as the reference substance cyclophosphamide.


Cyclophosphamide Therapeutic Effect Dose Level Nephritis Adult Animal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    K. Augsten andJ. Güttner,FDA-Hydrolyse zum fluoreszenzphotometrischen Nachweis einer Zellmembranalteration bei Peritonealmakrophagen, Acta histochem.52, 79–87 (1975).PubMedGoogle Scholar
  2. [2]
    K. Augsten, J. Güttner andR. Bimberg,Rasterelektronenmikroskopischer Nachweis von experimentell induzierten Membranalterationen an Mäuseerythrozyten, Acta histochem. Suppl. XVII, 249–254 (1976).Google Scholar
  3. [3]
    K. Augsten, J. Güttner andH.-P. Schröer,Methode zur immunfluoreszenzphotometrischen Bestimmung der Glomerulonephritis, Z. Immun.-Forsch.144, 323–328 (1972).Google Scholar
  4. [4]
    L. Bankir andN. Farman,Heterogenite des glomerulus chez le lapin, Arch. Anat. micr. Morphol. exper.62, 281–291 (1973).Google Scholar
  5. [5]
    A. Beickert, E. Günther andM. Müller,Vergleichende therapeutische Untersuchungen bei NZB/NZW-Hybridmäusen: Azathioprin, Zyklophosphamid und Dexamethason, Dt. Gesundh.-Wesen28, 634–637 (1973).Google Scholar
  6. [6]
    M.M. Beyer, A.D. Steinberg, A.D. Nicastri andE.A. Friedman,Unilateral Nephrectomy: Effect on Survival in NZB/NZW Mice, Science198, 511–513 (1977).PubMedGoogle Scholar
  7. [7]
    T.P. Casey,Immunosuppression by Cyclophosphamide in NZB×NZW Mice with Lupus Nephritis, Blood32, 436–444 (1968).PubMedGoogle Scholar
  8. [8]
    R. Gabriel,1-Methylisatin-3-thiosemicanbazone Treatment of NZB×NZW Hybrid Mice, Brit. J. exper. Pathol.52, 271–275 (1971).Google Scholar
  9. [9]
    A.E. Gabrielsen, A.S. Lubert andC.T. Olsen,Suppression of Murine Lupus Erythematosus by Dactinomycin, Nature264, 439–440 (1976).PubMedGoogle Scholar
  10. [10]
    M.C. Gelfand andA.D. Steinberg,Therapeutic Studies in NZB/W Mice. II. Relative Efficacy of Azathioprine, Cyclophosphamide and Methylprednisolone, Arthr. Rheumat.15, 247–252 (1972).Google Scholar
  11. [11]
    M.C. Gelfand, A.D. Steinberg, R. Nagle andJ.H. Knepshield,Therapeutic Studies in NZB/W Mice. I. Synergy of Azathioprine, Cyclophosphamide and Methylprednisolone in Combination, Arthr. Rheumat.15, 239–246 (1972).Google Scholar
  12. [12]
    J. Güttner,Neue Aspekte zur Immuntherapie der chronischen Immunkomplexnephritis (IKN). 1. Immunologische Grundlagen, Dt. Gesundh.-Wesen33, 534–540 (1978).Google Scholar
  13. [13]
    J. Güttner andK. Augsten,Unilateral nephrektomierte NZB-Hybriden als Testobjekt für immunsuppressive (antiglomerulonephritische) Pharmaka, Z. Versuchstierk.14, 263–270 (1972).Google Scholar
  14. [14]
    J. Güttner andK. Augsten,Alkylating Anticancer Agents and Phagocytosis. III. Stabilizing Effect of 1.2-Substituted 5-Bis[ β-chloroethyl)-amino-benzimidazole Derivatives on Erythrocytes in vivo, J. reticulbendoth. Soc.13, 91–97 (1973).Google Scholar
  15. [15]
    J. Güttner andH. Heinecke The Biological Signification in NZB Hybrids of the Autoimmune Nephropathies Accelerated by BCG, in:Antigen-Antibody Reaction (Eds. H. Ambrosius, K. Malberg and H. Schäffner; Wiss. Beitr. Karl-Marx-Universität, Reihe Biowiss.-Med., Leipzig, 1971), pp. 124–125.Google Scholar
  16. [16]
    J. Güttner, K. Augsten, R. Bimberg andP. Lange,Modification of the Surface Structure of Murine Peritoneal Macrophages Following Chemotherapy, Exper. Pathol.11, 209–214 (1975).Google Scholar
  17. [17]
    J. Güttner, H. Heinecke, W. Küchler andW. Werner,Immunosuppressive Effects of Barbituric Acid Derivatives. II. Effect of 1.3-Bis(piperidino-methyl)-5-ethyl-5-phenyl-barbituric Acid on Humoral and Cell Mediated Immunity in Mice, Chemotherapy19, 305–313 (1973).PubMedGoogle Scholar
  18. [18]
    B.H. Hahn, M.K. Bagby, T.R., Hamilton andC.K. Osterland,Comparison of Therapeutic and Immuno-suppressive Effects of Azathioprine, Prednisolone and Combined Therapy in NZB/NZW, Arthr. Rheumat.16, 163–170 (1973).Google Scholar
  19. [19]
    B.H. Hahn, L. Knotts, M. Ng andT.R. Hamilton,Influence of Cyclophosphamide and Other Immuno-suppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice, Arthr. Rheumat.18, 145–152 (1975).Google Scholar
  20. [20]
    M. Hara,Persistent Glomerular Changes after Acute Glomerulonephritis: a Histometrical Study of 34 Autopsy Cases, Beitr. pathol. Anat. allg. Pathol.147, 133–144 (1972).Google Scholar
  21. [21]
    R.E. Horowitz, E.L. Dubois, J. Wiener andL. Strain,Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus, Labor. Invest.21, 199–206 (1969).Google Scholar
  22. [22]
    L.W. Klassen, D.R. Budman, G.W. Williams, A.D. Steinberg andN.L. Gerber,Ribavirin: Efficacy in the Treatment of Murine Autoimmune Disease, Science195, 787–788 (1977).PubMedGoogle Scholar
  23. [23]
    I. Krumhaar, P. Reinschke, H.G. Peschel, F. Otto andH. Schwedtke,Zur Problematik der klinischen und morphologischen Klassifizierung und Verlaufsbeobachtung von Glomerulonephritiden, Dt. Gesundh.-Wesen26, 333–341 (1971).Google Scholar
  24. [24]
    E. Lemmel, E.R. Hurd andM. Ziff,Differential Effects of 6-Mercaptopurine and Cyclophosphamide on Autoimmune Phenomena in NZB Mice, Clin. exper. Immunol.8, 355–362 (1971).Google Scholar
  25. [25]
    A.R. McGiven,Blood Coagulation and the Effect of Warfarin Treatment on Renal Disease in NZB/NZW Mice, Brit. J. exper. Pathol.48, 552–555 (1967).Google Scholar
  26. [26]
    A.D. Morris, C. May andJ. Esterly,Mechanisms and Quantitation of Reduction in NZB/NZW nephritis by Cyclophosphamide, Arthr. Rheumat.15, 119–120 (1972).Google Scholar
  27. [27]
    W. Ozegowski, D. Krebs andM. Wunderwald,Aminosäureantagonisten. II. β-[5-(6)-Bis(β-chloräthyl)-amino-benzimidazolyl-(2)-Dl-alanin und Derivate als potentielle Cytostatica, J. prakt. Chem. [4]20 166–177 (1963).Google Scholar
  28. [28]
    C.L. Pirani, V.E. Pollak andF.D. Schwartz,The Reproducibility of Semiquantitative Analysis of Renal Histology, Nephron1, 230–237 (1964).Google Scholar
  29. [29]
    R. Risdon,Quantitation of Histological Changes in the Glomeruli in Renal Biopsy Specimens from Children: Total and Differential Glomerular Cell Counts, J. Pathol.114, 185–197 (1974).PubMedGoogle Scholar
  30. [30]
    P. Russell andJ.D. Hicks,Cyclophosphamide Treatment of Renal Disease in (NZB×NZW)F 1 Hybrid Mice, Lancet1, 440–446 (1968).PubMedGoogle Scholar
  31. [31]
    R. Russel, J.D. Hicks andF.M. Burnet,Cyclophosphamide Treatment of Kidney Disease in (NZB×NZW)F 1 Mice, Lancet1, 1279–1284 (1966).Google Scholar
  32. [32]
    R.S. Spendlove,Optimal Labeling of Antibody with Fluorescein Isothiocyanate, Proc. Soc. exper. Biol. Med.122, 580–583 (1966).Google Scholar
  33. [33]
    A.D. Steinberg, M.C. Gelfand, J.A. Hardin andD.T. Lowenthal,Therapeutic Studies in NZB/W Mice. III. Relationship Between Renal Status and Efficacy of Immunosuppressive Drug Therapy, Arthr. Rheumat.18, 9–14 (1975).Google Scholar
  34. [34]
    S.E. Walker andG.G. Bole,Influence of Natural and Synthetic Estrogens on the Course of Autoimmune Disease in the NZB/NZW Mouse, Arthr. Rheumat.16, 231–239 (1973).Google Scholar
  35. [35]
    S.E. Walker andG.G. Bole,Selective Suppression of Autoantibody Responses in NZB/NZW Mice Treated with Long-term Cyclophosphamide, Arthr. Rheumat.18, 265–272 (1975).Google Scholar
  36. [36]
    R.B. Zurier, D.M. Savadoff, S.B. Torrey andN.F. Rothfield,Prostaglandin E 1 Treatment of NZB/NZW Mice, Arthr. Rheumat.20, 723–728 (1977).Google Scholar

Copyright information

© Birkhäuser Verlag 1979

Authors and Affiliations

  • J. Güttner
    • 1
  1. 1.Forschungszentrum für Molekularbiologie und Medizin, Zentralinstitut für Mikrobiologie und Experimentelle, TherapieAkademie der Wissenschaften der DDRJena

Personalised recommendations